Methods of making orally available softgels includes pre-wetting a probiotic with an edible oil to produce a wetted supplement, wherein the edible oil is present in a range of 25% to 75% by weight of a total weight of the probiotic and edible oil, heating the wetted supplement to a temperature in a range of 35? C. to 40? C., blending the wetted supplement and a molten chocolate component together to produce a liquid fill material, encapsulating the liquid fill material in a softgel coating to produce an orally available softgel, and cooling the orally available softgel to have a softgel capsule shell comprising 5% to 15% by weight water. The fill material is a solid at room temperature in the cooled orally available softgel.

The present invention relates to a composition comprising a Leuconostoc citreum strain or a culture thereof as an active ingredient for preventing, improving or treating fibrosis, specifically pulmonary fibrosis, renal fibrosis or hepatic fibrosis.

According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various fibrosis, the composition may be usefully used as a composition for the treatment, prevention, improvement, or the like of fibrosis in humans or animals.

The present disclosure relates to an Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease and uses thereof. Since the Akkermansia muciniphila strain, the intestinal microorganism of the present disclosure, shows an effect of improving movement control and cognitive abilities as well as memory in an animal model having a degenerative brain disease such as Parkinson's disease and Alzheimer's disease, it can be useful in the prevention or treatment of brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc. In addition, it was confirmed in the present disclosure that compared to the Akkermansia muciniphila strain cultured in a mucin-containing medium, that cultured in a mucin-free medium showed a remarkable effect of improving hyperlipidemia, fatty liver, obesity, and hyperglycemia induced in a mouse model by high-fat diet when administered orally (in vivo). Accordingly, the present disclosure is expected to be very useful in relevant industries as a particular composition of culture medium and an optimized obligatory anaerobic culture method have been developed through the present disclosure.

Aspects of the disclosure relate to a composition comprising 20-60% w/w of fat combined with a nitric oxide synthase inhibitor. Method aspects of the disclosure relate to a method for inducing heart failure with preserved ejection fraction in an experimental laboratory animal, the method comprising administering a composition of the disclosure or a composition comprising 10-60% w/w of fat and a composition comprising a nitric oxide synthase inhibitor to the laboratory animal.

Aspects of the disclosure relate to a composition comprising 20-60% w/w of fat combined with a nitric oxide synthase inhibitor. Method aspects of the disclosure relate to a method for inducing heart failure with preserved ejection fraction in an experimental laboratory animal, the method comprising administering a composition of the disclosure or a composition comprising 10-60% w/w of fat and a composition comprising a nitric oxide synthase inhibitor to the laboratory animal.

A digestive product includes a probiotic component and an immune modulator, such as transfer factor and/or a nanofraction immune modulator. The digestive product may also contain a prebiotic component, such as one or more of galactooligosaccharides, xylooligosaccharides, and fructooligosaccharides. The probiotic component may be encapsulated, such as probiotic micro beadlets.

A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.

A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.

Animal feed blocks composed of feed pellets are formed by conditioning a meal of a particulated animal feed mixture through heating the meal using steam to cause at least one of the feed components in the feed mixture to bind the meal. The heated meal is mechanically forced through a die to compress the meal into heated pellets. The heated pellets are collected in a pre-formed mold and are compressed in their heated state resulting in the pellets combining to form the animal feed block in the shape of the mold. Systems may use a pellet mill and a hydraulic press where conditioning and pellet formation takes place in the pellet mill and formation of the animal feed block is through compressing a collection of heated pellets using the hydraulic press.

A method of using ZnO particles for the treatment of colon cancer and a method of using the particles for reducing the concentration of an organic contaminant in an aqueous solution is described. The ZnO particles are substantially spherical and may have nanopetals that provide a nanoflower morphology. The synthesis and characterization of the ZnO particles is also discussed.